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ABSTRACT
IL-10 is a key immune-regulatory cytokine, and its gene
polymorphisms correlate with severity of clinical GVHD.
IL-10 is made by a variety of donor and host cells, but
the functional relevance of its source and its role in the
biology of acute GVHD are not well understood. We
used preclinical models to examine the relevance of IL-
10/ in donor and host cellular subsets on the severity
of GVHD. IL-10/ in host tissues or in the donor grafts
did not alter donor Teff-mediated severity of GVHD.
Furthermore, neither host-derived nor donor Teff-de-
rived IL-10 was required for regulation of GVHD by WT
CD4CD25 donor Tregs. By contrast, Treg-derived IL-
10, although not obligatory, was necessary for optimal
reduction of GVHD by mature donor Tregs. Importantly,
IL-10 from donor BM grafts was also critical for optimal
donor Treg-mediated suppression of GVHD. Together,
these data suggest that IL-10 does not contribute to
the induction of GVHD severity by the Teffs. However,
donor BM graft and Treg-derived IL-10 are important
for donor Treg-mediated suppression of GVHD. J. Leu-
koc. Biol. 91: 667–675; 2012.
Introduction
Allogeneic BMT is a curative, therapeutic option for hemato-
logical malignancies [1, 2]. The donor T lymphocytes elimi-
nate host malignancies but also concurrently cause GVHD [3],
the major side-effect of allogeneic BMT [1, 4, 5]. A large num-
ber of proinflammatory cytokines and alloreactive donor T
cells are involved in the pathophysiology of GVHD [5]. Several
inflammatory cytokines, such as IL-1, TNF-, IL-6, and IFN-,
are elevated after allogeneic BMT and are known to perpetu-
ate GVHD through direct cytotoxic effects on host tissues and
also by activation and priming of immune effector cells [4,
6–8]. Whereas the role of proinflammatory cytokines in the
biology of GVHD is well appreciated, the role of immune-regu-
latory cytokines, such as IL-10 and TGF-, has not been as well
studied [9–11].
IL-10 was first identified by Mosmann and colleagues [12,
13] and subsequently named as IL-10 following the cloning of
its cDNA. IL-10 can be produced by virtually all T cell subsets,
including Th1, Th2, Th17, Th9, Teffs, and CD425Foxp3
Tregs and induced regulatory Tr1 cells. In addition, tissue epi-
thelial cells can synthesize IL-10 under certain circumstances
[14, 15]. IL-10 primarily targets leukocytes, has broad immune-
regulatory effects [15–17], and has been implicated directly in
the regulation of many experimental and human inflammatory
diseases [15, 17, 18].
Several lines of strong, correlative data suggest that IL-10
may be relevant in the induction and severity of clinical
GVHD. For example, IL-10 polymorphisms in the recipients of
HLA-matched sibling transplants are associated with acute and
chronic GVHD, whereas serum levels of IL-10 are elevated in
patients with acute GVHD [19–24] and in autologous GVHD
[25, 26]. Experimental data demonstrate a dose-dependent
modulation of GVHD by exogenous IL-10 [9, 27]. Administra-
tion of low doses of IL-10 suppressed GVHD, whereas higher
doses exacerbated severity of GVHD in MHC disparate BMT
[9]. IL-10 has also been implicated in the suppression of
GVHD by Tr1 cells, G-CSF analogues, inverse vaccination, or
eosinophil cationic protein [28–32]. However, the role of en-
dogenous sources of IL-10 in modulating GVHD biology and
mortality remains poorly understood.
The balance between alloreactive donor Teffs and donor-
derived, natural CD425Foxp3 T cells (Tregs) has been
shown to modulate the severity of GVHD [6, 33–36]. Tregs use
diverse mechanisms in mediating their regulatory functions
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[37]. Depending on the context, IL-10 has been implicated in
mediating Treg-induced immune regulation [35]. The mecha-
nisms for Treg-mediated suppression of GVHD are largely un-
known. Specifically, whether IL-10 plays an important role in
Treg-mediated reduction of GVHD severity is not well under-
stood.
We carefully examined the cellular sources and biological role
of endogenously derived IL-10 in the induction of acute GVHD
by the cytopathic donor Teffs and its regulation by the donor
CD4

25 Tregs. We demonstrate that neither donor- nor host-
derived IL-10 modulates GVHD mediated by alloreactive, cyto-
pathic Teffs in the absence of donor CD425Foxp3 Tregs. By
contrast, donor-derived IL-10, either from the mature Tregs or




Female B6 (H-2b, CD45.2), B6-background, IL-10/ (B6.129P2-
Il10tm1Cgn/J, IL-10KO, H-2b, CD45.2), and C3H.SW (H-2b, CD45.2,
CD229.1) mice were purchased from The Jackson Laboratory (Bar Har-
bor, ME, USA). B6-Ly5.2/Cr (B6-CD45.1, H-2b, CD45.1) mice were pur-
chased from NCI-Frederick (Frederick, MD, USA). All animal work must
have been conducted according to institutional IACUC guidelines of the
University of Michigan (Ann Arbor, MI, USA), Protocol #10006. The IA-
CUC Institutional Review Board Committee specifically approved this study.
Antibodies and flow cytometric analysis
FITC-, PE-, PerCP-Cy5.5 or allophycocyanin-conjugated mAb to mouse CD4
(clone; RM4-4), CD8a (53-6.7), CD25 (PC61.5), CD45.1 (A20), and CD45.2
(104) were purchased from eBioscience (San Diego, CA, USA). Anti-mouse
CD229.1 (30C7) was purchased from BD PharMingen (San Diego, CA,
USA). Spleen or BM cells were incubated with anti-CD16/CD32 (2.4G2; Fc
block, BD PharMingen) mAb for 15 min at 4°C in staining buffer (2% FCS-
containing PBS), and then the cells were stained with fluorochrome-conju-
gated mAb for 15 min at 4°C in the staining buffer. After washing, cells
were fixed with FACS lysing solution (BD Biosciences, San Diego, CA,
USA) [38]. For intracellular Foxp3 staining, the following procedure was
performed after cell-surface staining: fixed cells were washed with permea-
bilization buffer (eBioscience) and stained with PE-conjugated anti-Foxp3
mAb (FJK-16s; eBioscience) for 30 min at 4°C. The cells were washed with
permeabilization buffer and staining buffer (2) and resuspended with
staining buffer for analysis. Cells were analyzed on a C6 flow cytometer
(Accuri Cytometers, Ann Arbor, MI, USA).
BM chimeras
Recipient mice (B6-Ly5.2/Cr) were irradiated (137Cs source) with 11 Gy
TBI before transplant of syngeneic BM cells [38]. Donor BM cells were
harvested from femurs and tibias of donor mice, washed, and counted, and
cells (5106) were infused into recipient mice through the tail vein. Recip-
ient mice were maintained on acidified water (pH 3) for 3 weeks. Donor
hematopoietic cell engraftment was confirmed using peripheral blood by
flow cytometry, 2–3 months after transplantation. Anti-CD45.1 or -CD45.2
mAb were used for identification of donor-derived white blood cells. All
animal studies were performed per the institutional IACUC guidelines of
the University of Michigan.
BMT
Recipient mice were irradiated (137Cs source) with 9 to 11 Gy TBI, 1 day
before BMT [8, 38]. Donor BM cells were harvested from femurs and tib-
ias, and T cells in the BM were removed magnetically using CD90.2 mi-
crobeads (Miltenyi Biotec, Auburn, CA, USA) and a MACS LS column
(Miltenyi Biotec). Spleen T cells were magnetically isolated using MACS LS
or LD columns (Miltenyi Biotec). Pan T cell isolation kit (Miltenyi Biotec)
and biotin anti-CD25 (clone 7D4, BD PharMingen) were used for CD25-
depleted T cell isolation. CD8a T cell isolation kit and CD4CD25 Treg
isolation kit (Miltenyi Biotec) were used for CD8 T cell isolation and
CD4CD25 T cell isolation, respectively. Purities of isolated T cells were
checked by flow cytometry, and T cell numbers were determined based on
cell count and purity. Syngeneic or allogeneic BM and T cells were resus-
pended with L-15 media (Mediatech, Manassas, VA, USA) and infused
through the tail vein (250 l/mouse). Host mice were housed in sterilized
microisolator cages and maintained on acidified water (pH 3) for 3
weeks [8]. Survival was monitored daily, and clinical GVHD was assessed
weekly [38]. All animal studies were performed per the institutional
IACUC guidelines of the University of Michigan.
In vitro suppression assay
CD4CD25 and CD4CD25 T cells were isolated from spleen cells from
B6(WT) or IL-10KO animals using the CD4CD25 Treg isolation kit
(Miltenyi Biotec) [8]. For the anti-CD3e-stimulated suppression assay,
CD4CD25 T cells were serially diluted from 1  104–1250 cells/well and
incubated with B6(WT) 1  104 CD4CD25 T cells and 5  104 irradi-
ated (30 Gy), syngeneic B6 spleen cells in the presence of 2 g/ml anti-
CD3e mAb (clone 145-2C-11; eBioscience) for 72 h. For the allo-stimulated
suppression assay, CD4CD25 T cells were serially diluted from 2  104–
2500 cells/well and incubated with B6(WT) 2  104 CD4CD25 T cells
and 1  103 allogeneic B6D2F1 or BALB/c BM DCs for 120 h. Incorpora-
tion of 3H-thymidine (1 Ci/well) by proliferating cells was measured dur-
ing the last 6 h of culture [8].
In vivo Treg expansion
C3H.SW recipient mice were irradiated (10 Gy; Day 1) and transplanted
B6(WT) 1  106 CD25-depleted T cells and B6-CD45.1 0.25  106
CD4CD25 T cells with 5  106 TCD BM from B6(WT) or IL-10KO mice.
On day 10, 17, or 24 post-BMT, a phenotype of the spleen cells was col-
lected, counted, and analyzed by flow cytometry. Donor Tregs were defined
as CD45.1CD4Foxp3 cells [38].
Histology
Formalin-preserved gut, liver, and skin were embedded in paraffin, cut into
5 m-thick sections, and stained with H&E for histologic examination.
Slides were coded without reference to prior treatment and examined in a
blinded manner by a pathologist (C. Liu). A semiquantitative scoring sys-
tem was used to assess the following abnormalities known to be associated
with GVHD.
Statistical analysis
Student’s t test was used for the statistical analysis of in vitro data. The log-
rank test was used to analyze survival data. P  0.05 was considered statisti-
cally significant.
RESULTS
Host-derived IL-10 is dispensable for induction of
GVHD
IL-10 can be derived from the host hematopoietic or the non-
hematopoietic cells [15]. Host hematopoietic-derived APCs are
known to modulate donor T cell responses [5, 39]. As IL-10
secretion by APCs has been suggested to alter T cell responses,
we first determined whether IL-10 production by only the host
hematopoietic cells plays a critical role in modulating GVHD
668 Journal of Leukocyte Biology Volume 91, April 2012 www.jleukbio.org
[40]. To this end, we generated [IL-10/ B63B6] (such that
only the hematopoietic-derived cells were incapable of produc-
ing IL-10) and the control [WTB63B6] chimeras and 3
months later, used them as recipients in an allogeneic BMT.
The chimeras were conditioned and transplanted with TCD
BM and donor T cells, which were rigorously depleted of
CD25 cells (to eliminate any potential confounding effects of
Tregs) from syngeneic B6 or MHC-matched, multiple minor-
mismatched C3H.SW allogeneic donors, as in Materials and
Methods. As shown in Fig. 1A, the [IL-10/ B63B6] and the
[WTB63B6] recipients demonstrated similar mortality from
GVHD (P0.38). The severity of clinical and histopathological
GVHD was similar regardless of the ability of hosts to make
IL-10 (data not shown).
We next determined whether IL-10 production from all of
the host tissues (hematopoietic and nonhematopoietic cells)
altered the severity of GVHD after allogeneic BMT. To this
end, we used IL-10KO recipients so that none of the host-de-
rived cells can make any IL-10. Lethally irradiated WT or IL-
10/ B6 animals were transplanted with TCD BM and CD25-
depleted T cells from syngeneic B6 or MHC-matched, multiple
minor-mismatched C3H.SW allogeneic donors, as in Materials
and Methods. As shown in Fig. 1B, there was no significant
difference in GVHD-induced mortality in the WT and IL-
10/ hosts (P0.25). Collectively, these data demonstrate
that neither host hematopoietic alone nor the host nonhema-
topoietic and hematopoietic-derived IL-10 play a critical role
in modulating the severity of GVHD caused by alloreactive
Teffs.
Impact of donor-derived IL-10 on GVHD severity
Antigen-primed T cells show higher expression of IL-10 than
naïve T cells [14]. We therefore tested the hypothesis that lack
of expression of IL-10 by alloreactive cytopathic donor Teffs
will aggravate GVHD mortality. C3H.SW animals were lethally
irradiated and transplanted with TCD BM and T cells from the
syngeneic C3H.SW donors. The allogeneic C3H.SW animals
received TCD BM from WT B6 animals along with T cells that
were rigorously depleted of CD25 cells (to eliminate any po-
tential confounding effects from Tregs) from WT B6 or IL-
10/ B6 donors, such that only the donor-alloreactive cyto-
pathic T cells were incapable of contributing IL-10. Contrary
to our hypothesis, inability of alloreactive donor T cells to
make IL-10 did not affect GVHD mortality (Fig. 2A; P0.41)
or clinical severity (score of 5.50.8 vs. 6.11, 4.30.6 vs.
4.10.7, 5.20.9 vs. 5.10.5, 6.30.4 vs. 5.91.1, on Days 7,
14, 28, and 42, respectively). These results were also reflected
in the similar histopathological damage (data not shown). Fur-
thermore, proliferation of WT and IL-10/ T cells was simi-
lar upon in vitro allogeneic stimulation with BALB/c DCs
(39,653948 vs. 42,2212969; P0.7), demonstrating that the
inability of the T cells to make IL-10 did not affect their intrin-
sic alloreactivity.
We next determined whether the expression of IL-10 by the
nonalloreactive T cells from the donor modulated severity of
GVHD. The C3H.SW animals were conditioned and trans-
planted as above. The allogeneic recipients were transplanted
with WT CD25-depleted B6 T cells, along with TCD BM from
the WT B6 or IL-10/ animals. As shown in Fig. 2B, the lack
of expression of IL-10 by donor BM-derived cells did not affect
GVHD mortality (P0.08). Although the animals that received
IL-10
/
BM appeared to demonstrate a trend toward greater
mortality in this experiment, this was not apparent in repeat
experiments, and importantly, the histopathological analyses of
the GVHD target organs, the liver, and GI tract demonstrated
similar GVHD-specific damage (Fig. 2C). Furthermore, the
allogeneic recipient animals in a second [MHC disparate,
B63F1] BMT model, which were transplanted with IL-10/
BM, also demonstrated similar GVHD mortality (Fig. 2D). To-
gether, these data demonstrate that absence of IL-10 secretion
by cytopathic alloreactive, mature donor T cells or the BM-
derived cells does not modulate GVHD.
IL-10 secretion by donor Tregs is required for their
optimal regulation of GVHD
The severity of GVHD is determined by the balance between
the mature, alloreactive, cytopathic T cells and Tregs from the
donors [5, 6]. IL-10 has been implicated as one of the mecha-
nisms for Treg-mediated suppression [37]. We therefore deter-
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Figure 1. Effect of host-derived IL-10 on GVHD. (A) B6(WT) BM
chimera recipients [B63Ly5.2] were irradiated (9 Gy) on Day 1 and
transplanted 5  106 syngeneic B6 BM (; n6) or allogeneic
C3H.SW 5  106 TCD BM  0.2  106 CD8 T cells (F; n5). B6-IL-
10KO BM chimera recipients [IL-10KO3Ly5.2] were irradiated (9
Gy) on Day 1 and transplanted allogeneic C3H.SW 5  106 TCD
BM  0.2  106 CD8 T cells (f; n5). Survival was monitored daily.
Data from one of two similar experiments are shown. F versus f, P 
0.6186. (B) B6(WT) recipients were irradiated (10 Gy) on Day 1 and
transplanted 5  106 syngeneic B6 BM (; n9) or allogeneic
C3H.SW 5  106 TCD BM  0.2  106 CD8 T cells (F; n7). B6-IL-
10KO recipients were irradiated (10 Gy) on Day 1 and transplanted
allogeneic C3H.SW 5  106 TCD BM  0.2  106 CD8 T cells (f;
n7). Survival was monitored daily. Data from one of three similar
experiments are shown. F versus f, P  0.2516.
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mined whether IL-10 expression by donor Tregs is critical for
regulation of GVHD. The C3H.SW animals were irradiated
and transplanted with TCD BM and CD25-depleted T cells
from WT B6 animals. There was no intrinsic difference in the
expression of CD25 and Foxp3 between the WT and IL-
10/ animals at baseline. Hence, donor-derived CD25CD4
natural Tregs (98–99% of these cells were Foxp3) from WT
B6 or IL-10/ B6 animals were transplanted at 1:4 and 1:16
ratios with CD25 alloreactive T cells. As expected, allogeneic
animals that received a WT Treg:Teff ratio of 1:4 demon-
strated significant protection from GVHD mortality when com-
pared with animals that did not receive any Tregs (20% vs.
80%; P0.0010). As shown in Fig. 3A, infusion of lower ratios
of Tregs:Teffs (1:16) did not offer any survival benefit
(P0.25), demonstrating that the ability of Tregs to suppress
GVHD is a function of the balance between Tregs and Teffs.
By contrast, infusion of IL-10/ Tregs at 1:16 and 1:4 ratios
with WT Teffs induced similar GVHD mortality when com-
pared with control animals that did not receive any Tregs, thus
demonstrating a failure of protection from GVHD by the IL-
10/ Tregs (Fig. 3B; P0.4). However, further increasing the
ratio of IL-10/ Tregs: WT Teffs (to 1:2) modestly mitigated
GVHD mortality (50% vs. 90%; P0.03) when compared with
animals that did not receive any Tregs. This GVHD-protective
effect of IL-10/ Tregs at a 1:2 ratio was nonetheless still in-
ferior to that afforded by WT Tregs at a lower ratio (1:4 50%
vs. 20% mortality, respectively; Figs. 3A and B). By contrast,
Tregs suppressed T cell responses, regardless of the allogeneic
stimulus (Supplemental Fig. 1). Furthermore, consistent with
previous data demonstrating lack of requirement of IL-10 se-
cretion by Tregs in suppressing in vitro alloresponses [35, 41,
42], IL-10/ Tregs demonstrated equivalent suppression of
nonspecific T cell proliferation in vitro when compared with
WT Tregs (Fig. 3C). Furthermore, the WT and IL-10/ Tregs
demonstrated no significant differences in the surface expres-
sion of CTLA4 and glucocorticoid-induced TNFR (data not
shown). These data indicate that the reduced ability of IL-
10/ Tregs to suppress GVHD is likely, not because of a
Treg-intrinsic defect.
Donor Tregs mitigate GVHD induced by IL-10/
Teffs
IL-10/ alloreactive Teffs caused similar GVHD as the WT T
cells. We next examined whether this GVHD was amenable to
suppression by WT Tregs. The C3H.SW animals were lethally
irradiated and transplanted with IL-10/ CD25 T cells and
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Figure 2. Effect of donor-derived IL-10 on GVHD. (A) C3H.SW recipients were irradiated (10 Gy) on Day 1 and transplanted 5  106 synge-
neic C3H.SW BM (; n5), allogeneic B6(WT) 5  106 TCD BM  B6(WT) 1  106 CD25-depleted T cells (F; n10), or B6(WT) 5  106 TCD
BM  IL-10KO 1  106 CD25-depleted T cells (f; n12). Data from one of two similar experiments are shown. F versus f, P  0.4081. (B)
C3H.SW recipients were irradiated (10 Gy) on Day 1 and transplanted 5  106 syngeneic C3H.SW BM (; n5), allogeneic B6(WT) 5  106
TCD BM  B6(WT) 1  106 CD25-depleted T cells (F; n10), or IL-10KO 5  106 TCD BM  B6(WT) 1  106 CD25-depleted T cells (f;
n10). Survival was monitored daily. Data from one of two similar experiments are shown. F versus f, P  0.0785. (C) Day 24 pathology score of
C3H.SW recipients received 1  106 allogeneic B6(WT) CD25-depleted T cells along with B6 (WT; n4, black bar) or IL-10KO (n4, gray bar)
TCD BM. P  not significant. (D) B6D2F1 recipients were irradiated (11 Gy) on Day 1 and transplanted 5  106 syngeneic B6D2F1 BM (;
n11), allogeneic B6(WT) 5  106 TCD BM  B6(WT) 1  106 CD25-depleted T cells (F; n15), or IL-10KO 5  106 TCD BM  B6(WT) 1 
106 CD25-depleted T cells (f; n15). Survival was monitored daily. Data from three similar experiments were combined and shown. F versus f,
P  0.7699.
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TCD BM from WT B6 animals, along with or without
CD25CD4 Tregs from WT donors. As shown in Fig. 4, a vast
majority of the animals that received only the CD25 Teffs
from IL-10/ donors died from GVHD, whereas nearly all of
the allogeneic animals that received WT donor CD25 Tregs
along with the CD25 Teffs survived (mortality rate of 70% vs.
0%; P0.0080). These data demonstrate that donor Tregs that
express IL-10 can effectively mitigate GVHD, even when the
cytopathic Teffs do not express IL-10.
IL-10 by host is not required for Treg-mediated
GVHD suppression
Our data demonstrated that IL-10 expression by host hemato-
poietic or nonhematopoietic tissues is dispensable for induc-
tion of GVHD by Treg-depleted alloreactive Teffs. However,
IL-10 expression by APCs has been suggested to be important
for Treg-mediated suppression [40, 43]. Therefore, we next
analyzed whether expression of IL-10, only by host hematopoi-
etic-derived APCs or by all hematopoietic and nonhematopoi-
etic cells, is critical for Treg-mediated mitigation of GVHD.
The [IL-10/ B63WT B6] and the [WTB63WTB6] chime-
ras were transplanted with TCD BM and alloreactive
CD25CD8, along with, or without, CD25hiCD4 T cells
from allogeneic C3H.SW animals. Donor CD25hiCD4 Tregs
significantly suppressed GVHD in the [IL-10/ B63WT B6]
and [WTB63WTB6] chimeras, regardless of the ability of the
host hematopoietic-derived cells to make IL-10 (Fig. 5A;
P0.0005). Furthermore, as shown in Fig. 5B, donor
CD25hiCD4 Tregs also robustly suppressed GVHD mortality
in the IL-10/ and WT B6 animals (P0.01), demonstrating
that host-derived IL-10 is dispensable for Treg-mediated regu-
lation of GVHD.
Donor BM-derived IL-10 is required for optimal Treg-
mediated reduction in GVHD
In light of data demonstrating a role for APC-derived IL-10 in
Treg-mediated suppression [15, 40, 43] and given the lack of
impact of host-derived APCs in Treg-mediated regulation of
GVHD [38], we next examined whether donor BM-derived
IL-10 is critical for Treg-mediated suppression of GVHD. The
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Figure 3. Effect of donor Treg-derived IL-10 on GVHD. (A) C3H.SW recipients were irradiated (10 Gy) on Day 1 and
transplanted 5  106 syngeneic C3H.SW BM (; n5), allogeneic B6(WT) 5  106 TCD BM  B6(WT) 1  106 CD25-
depleted T cells (F; n10), B6(WT) 5  106 TCD BM  B6(WT) 1  106 CD25-depleted T cells  B6(WT) 0.25  106
CD4CD25 T cells (E; n14), or B6(WT) 5  106 TCD BM  B6(WT) 1  106 CD25-depleted T cells  B6(WT)
0.0625  106 CD4CD25 T cells (Œ; n6). Survival was monitored daily. Data from two combined similar experiments
are shown. F versus E, P  0.0010; F versus Œ, P  0.2544. (B) C3H.SW recipients were irradiated (10 Gy) on Day 1
and transplanted 5  106 syngeneic C3H.SW BM (; n5), allogeneic B6(WT) 5  106 TCD BM  B6(WT) 1  106
CD25-depleted T cells (F; n10), B6(WT) 5  106 TCD BM  B6(WT) 1  106 CD25-depleted T cells  IL-10KO 0.5 
106 CD4CD25 T cells (; n4), B6(WT) 5  106 TCD BM  B6(WT) 1  106 CD25-depleted T cells  IL-10KO
0.25  106 CD4CD25 T cells (; n5), or B6(WT) 5  106 TCD BM  B6(WT) 1  106 CD25-depleted T cells  IL-
10KO 0.0625  106 CD4CD25 T cells (Œ; n4). Survival was monitored daily. Data from one of two similar experi-
ments are shown. F versus , P  0.4115. (C) Suppressive activity of B6(WT) and IL-10KO Tregs. Serially diluted
(1104–1250/well) B6(WT) or IL-10KO CD4CD25 T cells were cocultured with 1  104 B6(WT) CD4CD25 T cells
in the presence of irradiated syngeneic 5  104 B6(WT) spleen cells and 2 g/ml anti-CD3e mAb for 72 h. Incorporation
of 3H-thymidine (1 Ci/well) by proliferating cells was measured during the last 6 h of culture.
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Figure 4. Donor Teff-derived IL-10 is not re-
quired for Treg-mediated suppression of
GVHD. C3H.SW recipients were irradiated (10
Gy) on Day 1 and transplanted 5  106 syn-
geneic C3H.SW BM (; n6), allogeneic
B6(WT) 5  106 TCD BM  B6(WT) 1  106
CD25-depleted T cells (F; n12), B6(WT)
5  106 TCD BM  B6(WT) 1  106 CD25-
depleted T cells  B6(WT) 0.25  106
CD4CD25 T cells (E; n7), B6(WT) 5 
106 TCD BM  IL-10KO 1  106 CD25-de-
pleted T cells (f; n12), or B6(WT) 5  106
TCD BM  IL-10KO 1  106 CD25-depleted T cells  B6(WT) 0.25  106 CD4CD25 T cells (; n7). Survival was monitored daily.
Data from two combined similar experiments are shown. F versus E, P  0.0080; f versus , P  0.0080.
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C3H.SW animals were lethally irradiated and transplanted with
CD25-depleted B6 WT Teffs, along with, or without, WT
CD25hiCD4 Tregs and TCD BM from IL-10/ B6 animals.
The clinical severity of GVHD (Fig. 6A) and the mortality (Fig.
6B; P0.9) and histopathological damage in the GI tract (Sup-
plemental Fig. 2) were similar, regardless of whether the recip-
ient animals received WT donor Tregs. These data demon-
strate that Tregs failed to suppress the clinical severity (Fig.
6A) or reduce GVHD mortality (Fig. 6B) in the animals that
received BM from IL-10/ donors.
We next explored the mechanisms for the requirement of do-
nor BM-derived IL-10 in Treg-mediated suppression of GVHD.
The stability of the expression of Foxp3 in Tregs is critical for
their regulatory function [44, 45]. Therefore, we first analyzed
whether the Foxp3 expression in donor Tregs was stable in the
absence of IL-10 production by donor BM cells. The expression
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Figure 5. Effect of host-derived IL-10 on Treg-mediated suppression of GVHD. (A) B6(WT) recipients were irradiated (10 Gy) on Day 1 and
transplanted 5  106 syngeneic B6 BM (; n9), B6-IL-10KO recipients were irradiated (10 Gy) on Day 1 and transplanted allogeneic C3H.SW
5  106 TCD BM  0.2  106 CD8 T cells (f; n12), or C3H.SW 5  106 TCD BM  0.2  106 CD8 T cells  0.1  106 CD4CD25 T cells
(; n12). Survival was monitored daily. Data from two similar experiments are combined and shown. f versus , P  0.0136. (B) B6(WT) BM
chimera recipients [B63Ly5.2] were irradiated (9 Gy) on Day 1 and transplanted 5  106 syngeneic B6 BM (; n5), allogeneic C3H.SW 5 
106 TCD BM  0.2  106 CD8 T cells (F; n6), or C3H.SW 5  106 TCD BM  0.2  106 CD8 T cells  0.1  106 CD4CD25 T cells (E;
n5). B6-IL-10KO BM chimera recipients [IL-10KO3Ly5.2] were irradiated (9 Gy) on Day 1 and transplanted allogeneic C3H.SW 5  106 TCD
BM  0.2  106 CD8 T cells (f; n6) or C3H.SW 5  106 TCD BM  0.2  106 CD8 T cells  0.1  106 CD4CD25 T cells (; n6). Survival
was monitored daily. Data from one of two similar experiments are shown. F versus E, P  0.0013; f versus , P  0.0005.
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D Figure 6. Effect of donor BM-derived IL-10 on Treg-mediated sup-
pression of GVHD. (A) C3H.SW recipients were irradiated (10 Gy)
on Day 1 and transplanted 5  106 syngeneic C3H.SW BM (;
n10), allogeneic B6(WT) 5  106 TCD BM  B6(WT) 1  106
CD25-depleted T cells (F; n20), B6(WT) 5  106 TCD BM 
B6(WT) 1  106 CD25-depleted T cells  B6(WT) 0.25  106
CD4CD25 T cells (E; n14), IL-10KO 5  106 TCD BM 
B6(WT) 1  106 CD25-depleted T cells (f; n15), or IL-10KO 5 
106 TCD BM  B6(WT) 1  106 CD25-depleted T cells  B6(WT)
0.25  106 CD4CD25 T cells (; n14). Body weight (BW) of
recipients was monitored weekly. Data from four similar experiments
were combined and shown. (B) C3H.SW recipients were irradiated (10 Gy) on Day 1 and transplanted 5  106 syngeneic C3H.SW BM (;
n4), allogeneic B6(WT) 5  106 TCD BM  B6(WT) 1  106 CD25-depleted T cells (F; n8), B6(WT) 5  106 TCD BM  B6(WT) 1  106
CD25-depleted T cells  B6(WT) 0.25  106 CD4CD25 T cells (E; n6), IL-10KO 5  106 TCD BM  B6(WT) 1  106 CD25-depleted T cells
(f; n5), or IL-10KO 5  106 TCD BM  B6(WT) 1  106 CD25-depleted T cells  B6(WT) 0.25  106 CD4CD25 T cells (; n7). Survival
was monitored daily. Data from one of two similar experiments were shown. F versus E, P  0.0037; f versus , P  0.4752; F versus f, P 
0.2806. (C and D) C3H.SW recipients were irradiated (10 Gy) on Day 1 and transplanted allogeneic B6(WT) 5  106 TCD BM  B6(WT) 1 
106 CD25-depleted T cells  B6-CD45.1 0.25  106 CD4CD25 T cells or IL-10KO 5  106 TCD BM  B6(WT) 1  106 CD25-depleted T cells  B6-
CD45.1 0.25  106 CD4CD25 T cells. Spleen cells were harvested, counted, and analyzed by flow cytometry on Days 10 ,17, and 24. Percentage
of Foxp3 cells in donor (CD45.1) CD4 T cells (C) and calculated donor Treg (CD45.1CD4Foxp3) numbers (D) was shown. Data from
one of two experiments are shown.
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of Foxp3 was stable in the infused, mature donor Tregs, regard-
less of whether the donor BM made IL-10 (Fig. 6C). We next
hypothesized that IL-10 secretion by donor BM is critical for the
maintenance of donor Treg numbers after BMT. Contrary to the
hypothesis, as shown in Fig. 6C, we found that equivalent num-
bers of donor Tregs were recovered from the spleens of the re-
cipients early after BMT (Day 10), and the total numbers of do-
nor Tregs were reduced significantly at later time-points (Day 17)
after BMT in the animals that received IL-10/ donor BM when
compared with the animals that received WT BM (7.51.1105
vs.3.82.3105; P0.041). However, the numbers of Foxp3
Tregs were reduced in both groups and were once again similar
(P0.7) at later time-points (on Day 24) between the groups,
suggesting that donor BM-derived IL-10 does not significantly
contribute to stable expression of Foxp3. We therefore next de-
termined the relevance of donor BM-derived IL-10 in the magni-
tude of donor Treg-mediated suppression of GVHD by increasing
the Treg:Teff ratio (1:2). As shown in Fig. 7, in contrast to lack of
protection at lower Treg ratios, enhancing the ratio of Tregs sup-
pressed GVHD mortality. Together, these data suggest that IL-10,
from engrafting donor BM cells, is required for an optimal
GVHD protection mediated by the infusion of mature donor
Tregs.
DISCUSSION
IL-10 is a key immune-regulatory cytokine that has been impli-
cated in the function of Tregs and in suppressing several im-
mune responses [15]. However, its source and role modulating
in vivo allogeneic responses, such as acute GVHD, are not well
understood. We demonstrate an important role for donor- but
not host-derived IL-10 in the severity of acute GVHD and its
regulation by donor Tregs. With the use of clinically relevant
murine models of GVHD, we show that (1) host-derived IL-10
does not play a critical role in the severity of GVHD, or (2) in
its regulation by donor Tregs, (3) donor Teff-derived and do-
nor BM-derived IL-10 does not contribute to the Teff-mediated
GVHD severity; (4) by contrast, Treg-intrinsic expression of
IL-10 and (5) donor BM-derived IL-10 are critical for optimal
suppression of GVHD by the donor CD425 Tregs.
The induction of acute GVHD is a direct consequence of
donor T cell responses to host alloantigens and the deregula-
tion of several cytokines [5]. The role of individual cytokines
in the biology and clinical severity of GVHD is increasingly
understood. A clinically relevant role for IL-10 in GVHD has
been suggested by several recent clinical observations. The
IL-10 gene polymorphisms in host and donors have implicated
a key role for IL-10 pathways in the severity of clinical acute
GVHD after matched-related and URD BMT [19, 20]. How-
ever, whether the identified polymorphisms result in quantita-
tive and/ or qualitative alterations in IL-10 from donor or host
is unclear. We now demonstrate that complete absence of
IL-10 from donor Treg or BM cells can modulate GVHD when
the donor graft contains mature CD425 Tregs and CD25–
Teffs. Thus, our data add clarity and provide insight into the
clinical observations about the role of IL-10 and GVHD. Fur-
thermore, our data, demonstrating an important role for do-
nor BM-derived IL-10, may also provide a potential explana-
tion for a seminal, clinical observation by Blazar and col-
leagues [46] on the impact of high spontaneous production of
IL-10 by the URD BM graft in causing reduced mortality after
clinical BMT.
Experimental studies with murine models have demon-
strated seemingly conflicting results about the role of IL-10 in
GVHD. Whereas infusion of exogenous IL-10 has demon-
strated protection at very low doses, higher doses aggravated
GVHD mortality in MHC-mismatched BMT [9, 27], These ex-
periments, nonetheless, did not evaluate the role of endoge-
nous IL-10. By contrast, infusion of IL-10/ donor T cells
without BM support caused enhanced mortality in sublethally
irradiated, MHC-disparate models of allogeneic BMT [9]. Our
data show that infusion of IL-10/ Teffs without Tregs did
not alter GVHD, whereas infusion of Tregs, which are IL-
10/, caused greater GVHD than WT Tregs. The distinctions
in the models aside, in the earlier study with IL-10/ donors,
pan T cells without CD25 depletion (Teffs and Tregs) were
transplanted [9]. Therefore the severe GVHD might be a con-
sequence of infusion of IL-10/ Tregs, along with Teffs. Our
results thus further expand the earlier observations.
Naturally occurring CD4CD25Foxp3 T cells (Tregs) are
a distinct CD4 T cell subset that causes potent suppression-
immune responses across multiple experimental models [34].
Tregs also cause potent suppression of GVHD across multiple
experimental models [34]. Clinical data indicate that donor
Tregs correlated with GVHD [47]. Furthermore, clinical trials
are currently under way to examine the ability of freshly iso-
lated or ex vivo-expanded Tregs to prevent GVHD [34, 48],



















Figure 7. Donor BM-derived IL-10 is necessary for optimal Treg-
mediated suppression of GVHD. C3H.SW recipients were irradi-
ated (10 Gy) on Day 1 and transplanted 5  106 syngeneic
B6D2F1 BM (; n16), allogeneic B6(WT) 5  106 TCD BM 
B6(WT) 0.4  106 CD25-depleted T cells (F; n21), B6(WT) 5 
106 TCD BM  B6(WT) 0.4  106 CD25-depleted T cells 
B6(WT) 0.2  106 CD4CD25 T cells (E; n16), IL-10KO 5 
106 TCD BM  B6(WT) 0.4  106 CD25-depleted T cells (f;
n21), or IL-10KO 5  106 TCD BM  B6(WT) 0.4  106 CD25-
depleted T cells  B6(WT) 0.2  106 CD4CD25 T cells (;
n13). Survival was monitored daily. Data from three similar exper-
iments were combined and shown. F versus E, P  0.0124; f ver-
sus , P  0.0001; F versus f, P  0.1792; E versus , P  0.3703.
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whereas a recent clinical study has demonstrated the clinical
feasibility of this approach after allogeneic BMT [49].
Tregs appear to use diverse mechanisms for mediating im-
mune regulation [37]. Among the diverse pathways, the criti-
cal pathway for Treg-mediated suppression of GVHD is not
clear. An earlier study suggested a key role for IL-10 in Treg-
mediated suppression of GVHD [35]. We now extend those
observations and demonstrate that the inferior ability of the
IL-10
/
Tregs could be overcome by enhancing their numbers
in the donor inoculum. Thus, our data show that IL-10 expres-
sion by the donor Tregs is necessary only for optimal suppres-
sion of GVHD. Our data did not specifically explore the role
of IL-10 in other Treg subset-mediated protection of GVHD
but when taken together, suggest that IL-10 is important for
Treg- and Tr1-mediated reduction in GVHD [28]. Further-
more, it remains to be determined whether the Treg-mediated
suppression of GVHD is also dependent on other suppressor
cytokines, such as TGF-, and/or predominantly through tar-
geting Teffs (by IL-2 consumption or cytolysis) or those that
primarily target APCs (such as decreased costimulation or anti-
gen presentation) [37].
We also demonstrate a novel role for donor BM-derived
IL-10 in mediating a Treg-induced reduction of GVHD. Our
data suggest that donor BM-derived IL-10 is required by the
donor Tregs to be more efficacious at smaller ratios of Treg:
Teffs after BMT. Future studies will determine which non-T
cellular subsets from the donor graft are the key producers of
IL-10. However, consistent with a previous report [38], host-
derived IL-10 was not important for Treg-mediated suppres-
sion of GVHD. These results, when taken together with previ-
ous reports, indicate that although interaction of Tregs with
the host BM-derived APCs [38] is important for induction of
Treg-mediated reduction of GVHD, the ability of these host
BM-derived APCs to make IL-10 is, however, not critical. The
dependence of donor BM-derived IL-10 is consistent with
other reports, demonstrating a role for IL-10 from hematopoi-
etic-derived APCs in mediating Treg function in the GI tract
[43, 50]. Future studies will determine whether this require-
ment is critical for the donor Treg function and migration to
the GI tract in reducing GVHD severity after allo-BMT.
In summary, we provide a novel perspective on the role of
immune-regulatory cytokine IL-10 in modulating GVHD. We
demonstrate that in the absence of donor Tregs, host- or do-
nor-derived IL-10 does not play an important role in the mod-
ulation of GVHD. However, IL-10 from donor Tregs or donor
BM is important for optimal Treg-mediated suppression of
GVHD. These observations might be relevant for an effective
use of Tregs in treating clinical GVHD.
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